zurück

Ivacaftor / tezacaftor / elexacaftor (new indication: cystic fibrosis; F508del mutation; heterozygous, and RF mutation; patients aged ≥ 6 - ≤ 11 years (in combination with ivacaftor))

Subject:

  • Active Substance: Ivacaftor / texacaftor / elexacaftor
  • Name: Kaftrio®
  • Therapeutic area: Cystic fibrosis
  • Pharmaceutical company: Vertex Pharmaceuticals (Germany) GmbH

Time table:

  • Start: 15.02.2022
  • Final decision by G-BA: 04.08.2022

Final decision:

  • No additional benefit proved